Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Hanker A, Castellino S, Joensuu H, Huober J, Brase J, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Groseclose M, Becker J, Garrett J, Estrada M, Moore P, Ericsson P, Koch J, Langley E, Singh S, Kim P, Frampton G, Sanford E, Owens P, Arteaga C. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res 2017; 23:4323-4334.
Apr 5, 2017HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Apr 5, 2017Clin Cancer Res 2017; 23:4323-4334
Hanker Ariella B, Castellino Stephen, Joensuu Heikki, Huober Jens, Brase Jan C, Majjaj Samira, Brohée Sylvain, Venet David, Brown David, Baselga José, Piccart Martine, Sotiriou Christos, Groseclose M Reid, Becker Jennifer, Garrett Joan T, Estrada Mónica Valeria, Moore Preston D, Ericsson Paula González, Koch James P, Langley Emma, Singh Sharat, Kim Phillip S, Frampton Garrett M, Sanford Eric, Owens Philip, Arteaga Carlos L
Palliative Primary Tumor Resection in Patients With Metastatic Colorectal Cancer: For Whom and When?
Tarantino I, Warschkow R, Gueller U. Palliative Primary Tumor Resection in Patients With Metastatic Colorectal Cancer: For Whom and When?. Ann Surg 2017; 265:e59-e60.
Apr 1, 2017Palliative Primary Tumor Resection in Patients With Metastatic Colorectal Cancer: For Whom and When?
Apr 1, 2017Ann Surg 2017; 265:e59-e60
Tarantino Ignazio, Warschkow Rene, Gueller Ulrich
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Baty F, Jörger M, Früh M, Klingbiel D, Zappa F, Brutsche M. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. J Transl Med 2017; 15:66.
Mar 30, 201724h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Mar 30, 2017J Transl Med 2017; 15:66
Baty Florent, Jörger Markus, Früh Martin, Klingbiel Dirk, Zappa Francesco, Brutsche Martin
Feasibility and effects of a combined adjuvant high-intensity interval/strength training in breast cancer patients: a single-center pilot study
Schulz S, Laszlo R, Otto S, Prokopchuk D, Schumann U, Ebner F, Huober J, Steinacker J. Feasibility and effects of a combined adjuvant high-intensity interval/strength training in breast cancer patients: a single-center pilot study. Disabil Rehabil 2017; 40:1501-1508.
Mar 21, 2017Feasibility and effects of a combined adjuvant high-intensity interval/strength training in breast cancer patients: a single-center pilot study
Mar 21, 2017Disabil Rehabil 2017; 40:1501-1508
Schulz Sebastian Viktor Waldemar, Laszlo Roman, Otto Stephanie, Prokopchuk Dmytro, Schumann Uwe, Ebner Florian, Huober Jens, Steinacker Jürgen Michael
Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients
Fehr M, Müller J, Knitel M, Fornaro J, Horber D, Koeberle D, Cerny T, Gueller U. Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients. Clin Colorectal Cancer 2017
Mar 21, 2017Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients
Mar 21, 2017Clin Colorectal Cancer 2017
Fehr Martin, Müller Joachim, Knitel Meinhard, Fornaro Jürgen, Horber Daniel, Koeberle Dieter, Cerny Thomas, Gueller Ulrich
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
Stathis A, Sessa C, Gargiulo P, Berardi S, Enoiu M, Xyrafas A, Catapano C, Allegrini S, Ackermann C, Mark M, Jörger M, Griguolo G, Homicsko K, von Moos R, Hess D, Swiss Group for Clinical Cancer Research (SAKK). Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. Invest New Drugs 2017; 35:766-772.
Mar 20, 2017Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
Mar 20, 2017Invest New Drugs 2017; 35:766-772
Stathis A, Sessa C, Gargiulo P, Berardi S, Enoiu M, Xyrafas A, Catapano C V, Allegrini S, Ackermann C J, Mark M, Jörger Markus, Griguolo G, Homicsko K, von Moos R, Hess Dagmar, Swiss Group for Clinical Cancer Research (SAKK)
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Drilon A, Früh M, Diebold J, Zeidler K, Velcheti V, Riess J, Gandara D, Zalcman G, Froesch P, Michels S, Monnet I, Popat S, Mazières J, Cabillic F, Muley T, Warth A, Shih J, Rothschild S, Karachaliou N, Rosell R, Pall G, Ou S, Yang J, Doebele R, Narayanan V, Camidge R, Owen D, Carbone D, Wolf J, Filleron T, Milia J, Besse B, Remon-Masip J, Jänne P, Mok T, Neal J, Wakelee H, Van Den Heuvel M, Karp D, Byoung C, Peled N, Awad M, Gautschi O. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol 2017; 35:1403-1410.
Mar 13, 2017Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Mar 13, 2017J Clin Oncol 2017; 35:1403-1410
Drilon Alexander, Früh Martin, Diebold Joachim, Zeidler Kristin, Velcheti Vamsidhar, Riess Jonathan W, Gandara David R, Zalcman Gérard, Froesch Patrizia, Michels Sebastian, Monnet Isabelle, Popat Sanjay, Mazières Julien, Cabillic Florian, Muley Thomas, Warth Arne, Shih Jin-Yuan, Rothschild Sacha I, Karachaliou Niki, Rosell Rafael, Pall Georg, Ou Sai-Hong Ignatius, Yang James C H, Doebele Robert C, Narayanan Vignhesh, Camidge Ross, Owen Dwight, Carbone David P, Wolf Juergen, Filleron Thomas, Milia Julie, Besse Benjamin, Remon-Masip Jordi, Jänne Pasi A, Mok Tony S K, Neal Joel W, Wakelee Heather A, Van Den Heuvel Michael, Karp Daniel D, Byoung Chul-Cho, Peled Nir, Awad Mark M, Gautschi Oliver
Secondary malignancies after rectal cancer resection with and without radiation therapy: A propensity-adjusted, population-based SEER analysis
Warschkow R, Gueller U, Cerny T, Schmied B, Plasswilm L, Putora P. Secondary malignancies after rectal cancer resection with and without radiation therapy: A propensity-adjusted, population-based SEER analysis. Radiother Oncol 2017; 123:139-146.
Mar 9, 2017Secondary malignancies after rectal cancer resection with and without radiation therapy: A propensity-adjusted, population-based SEER analysis
Mar 9, 2017Radiother Oncol 2017; 123:139-146
Warschkow Rene, Gueller Ulrich, Cerny Thomas, Schmied Bruno, Plasswilm Ludwig, Putora Paul Martin
3-year follow-up data of the Swiss Pompe Registry-analysis of the first 7 patients
Hundsberger T (2017). 3-year follow-up data of the Swiss Pompe Registry-analysis of the first 7 patients - T. Hundsberger, O. Scheidegger, D. Leupold, O. Findling, K. M. Roesler. Presented at: 23. Kongress des wissenschaftlichen Beirates der Deutschen Gesellschaft für Muskelerkrankungen, München, Deutschland
Mar 2, 20173-year follow-up data of the Swiss Pompe Registry-analysis of the first 7 patients
Mar 2, 201723. Kongress des wissenschaftlichen Beirates der Deutschen Gesellschaft für Muskelerkrankungen
Hundsberger Thomas
Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database
Keizman D, Daugaard G, Gillessen Sommer S, Mortensen J, Rouvinov K, Mermershtain W, Sarid D, Dresler H, Gottfried M, Cathomas R, Mueller J, Petersen P, Neiman V, Desax M, Rosenbaum E, Peer A, Reichegger H, Fosboel M, Omlin A. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database. Prostate Cancer Prostatic Dis 2017; 20:289-293.
Feb 28, 2017Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database
Feb 28, 2017Prostate Cancer Prostatic Dis 2017; 20:289-293
Keizman D, Daugaard G, Gillessen Sommer Silke, Mortensen J, Rouvinov K, Mermershtain W, Sarid D, Dresler H, Gottfried M, Cathomas R, Mueller J, Petersen P M, Neiman V, Desax M-C, Rosenbaum E, Peer A, Reichegger H, Fosboel M O, Omlin Aurelius
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study
Borgquist S, Regan M, Gelber R, Price K, Rabaglio M, Goldhirsch A, Coates A, Smith I, von Moos R, Ejlertsen B, Debled M, Láng I, Colleoni M, Garber J, Ahern T, Giobbie-Hurder A, Thürlimann B. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. J Clin Oncol 2017; 35:1179-1188.
Feb 13, 2017Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study
Feb 13, 2017J Clin Oncol 2017; 35:1179-1188
Borgquist Signe, Regan Meredith M, Gelber Richard D, Price Karen N, Rabaglio Manuela, Goldhirsch Aron, Coates Alan S, Smith Ian, von Moos Roger, Ejlertsen Bent, Debled Marc, Láng István, Colleoni Marco, Garber Judy E, Ahern Thomas P, Giobbie-Hurder Anita, Thürlimann Beat
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Fumagalli D, Di Cosimo S, de Azambuja E, de la Pena L, Nuciforo P, Brase J, Huober J, Baselga J, Piccart M, Loi S, Coccia-Portugal M, Chang T, Gomez H, Venet D, Ignatiadis M, Azim H, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Sotiriou C. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 2017; 3:227-234.
Feb 1, 2017RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Feb 1, 2017JAMA Oncol 2017; 3:227-234
Fumagalli Debora, Di Cosimo Serena, de Azambuja Evandro, de la Pena Lorena, Nuciforo Paolo, Brase Jan C, Huober Jens, Baselga José, Piccart Martine, Loi Sherene, Coccia-Portugal Maria Antonia, Chang Tsai-Wang, Gomez Henry, Venet David, Ignatiadis Michail, Azim Hatem A, Maetens Marion, Rothé Françoise, Salgado Roberto, Bradbury Ian, Pusztai Lajos, Harbeck Nadia, Sotiriou Christos
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
Morganstein D, Lai Z, Spain L, Diem S, Levine D, Mace C, Gore M, Larkin J. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 2017; 86:614-620.
Jan 27, 2017Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
Jan 27, 2017Clin Endocrinol (Oxf) 2017; 86:614-620
Morganstein D L, Lai Z, Spain L, Diem Stefan, Levine D, Mace C, Gore M, Larkin J
Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients
Gachechiladze M, Soltermann A, Weder W, Stahel R, Baty F, Kolář Z, Bouchal J, Langová K, Grygárková I, Kolek V, Škarda J, Jörger M. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients. Lung Cancer 2017; 105:31-38.
Jan 18, 2017Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients
Jan 18, 2017Lung Cancer 2017; 105:31-38
Gachechiladze Mariam, Soltermann Alex, Weder Walter, Stahel Rolf, Baty Florent, Kolář Zdeněk, Bouchal Jan, Langová Kateřina, Grygárková Ivona, Kolek Vítězslav, Škarda Josef, Jörger Markus
Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology
Droz J, Balducci L, Zulian G, Puts M, Payne H, Oudard S, Mottet N, Hughes S, Gillessen Sommer S, Albrand G, Aapro M. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. Eur Urol 2017; 72:521-531.
Jan 11, 2017Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology
Jan 11, 2017Eur Urol 2017; 72:521-531
Droz Jean-Pierre, Balducci Lodovico, Zulian Gilbert, Puts Martine, Payne Heather, Oudard Stephane, Mottet Nicolas, Hughes Simon, Gillessen Sommer Silke, Albrand Gilles, Aapro Matti
pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials
Reinisch M, Nekljudova V V, Untch M, Lederer B, Rhiem K, Schneeweiss A, Kümmel S, Jackisch C, Hanusch C, Denkert C, Blohmer J, von Minckwitz G, Huober J, Loibl S. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. Breast 2017; 32:73-78.
Jan 5, 2017pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials
Jan 5, 2017Breast 2017; 32:73-78
Reinisch Mattea, Nekljudova V Valentina, Untch Michael, Lederer Bianca, Rhiem Kerstin, Schneeweiss Andreas, Kümmel Sherko, Jackisch Christian, Hanusch Claus, Denkert Carsten, Blohmer Jens-Uwe, von Minckwitz Gunter, Huober Jens, Loibl Sibylle
Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012.
Bonadies N, Feller A, Rovó A, Ruefer A, Blum S, Gerber B, Stuessi G, Benz R, Cantoni N, Holbro A, Schmidt A, Lehmann T, Wilk C, Arndt V, NICER Working Group. Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. Cancer Epidemiol 2017; 46:85-92.
Jan 2, 2017Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012.
Jan 2, 2017Cancer Epidemiol 2017; 46:85-92
Bonadies Nicolas, Feller Anita, Rovó Alicia, Ruefer Axel, Blum Sabine, Gerber Bernhard, Stuessi Georg, Benz Rudolf, Cantoni Nathan, Holbro Andreas, Schmidt Adrian, Lehmann Thomas, Wilk C Matthias, Arndt Volker, NICER Working Group
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma
Abt D, Kraus M, Bader J, Besse A, Schmid H, Engeler D, Driessen C, Besse L (2017). Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma. Presented at: -, -
Jan 1, 2017Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma
Jan 1, 2017-
Abt Dominik, Kraus M, Bader J, Besse A, Schmid Hans-Peter, Engeler Daniel, Driessen Christoph, Besse L
Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms
Abt D, Kraus M, Bader J, Besse A, Schmid H, Engeler D, Driessen C, Besse L (2017). Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms. Presented at: -, -
Jan 1, 2017Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms
Jan 1, 2017-
Abt Dominik, Kraus M, Bader J, Besse A, Schmid Hans-Peter, Engeler Daniel, Driessen Christoph, Besse L
Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms
Abt D, Kraus M, Bader J, Besse A, Schmid H, Engeler D, Driessen C, Besse L (2017). Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms. Presented at: -, -
Jan 1, 2017Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms
Jan 1, 2017-
Abt Dominik, Kraus M, Bader J, Besse A, Schmid Hans-Peter, Engeler Daniel, Driessen Christoph, Besse L